Zydus Cadila gets USFDA nod for Carbamazepine extended release tablets
Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity.
New Delhi: Zydus Cadila Friday said it has received final approval from the US health regulator to market Carbamazepine extended-release tablets, used to treat certain types of seizures.
Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity.
Read Also: Zydus Wellness to sell shares worth Rs 2575 crore to Cadilla and three others
Zydus Cadila said the drug will be produced at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group has more than 248 drug approvals, and so far filed over 350 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Read Also: Zydus gets tentative USFDA nod to generic Esomeprazole Magnesium delayed-release capsules
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd